

Labetalol

CAUTION: High Administration Risk Rating														
Form	100mg per 20mL ampoule (5mg/mL)													
Reconstitution	Already in solution <ul style="list-style-type: none">• Draw up using a 5 micron filter needle• Use gloves when opening ampoules The solution should be clear and colourless. Inspect visually for particulate matter or discoloration prior to administration and discard if present.													
Compatibility & Stability	Glucose 5% (preferred) Sodium Chloride 0.9%													
Administration	IV Injection													
	Emergency use only. Use undiluted at a maximum rate of 50mg/min. Usual maximum total dose 200mg.													
	IV infusion													
	Using 1mg/mL solution. See possible preparations in Table below													
	<table><tr><th>Volume Labetalol 5mg/mL</th><th>Volume infusion fluid</th><th>Final volume 1mg/mL</th></tr><tr><td>50mL</td><td>200mL</td><td>250mL</td></tr><tr><td>60mL</td><td>240mL</td><td>300mL</td></tr><tr><td>100mL</td><td>400mL</td><td>500mL</td></tr></table>		Volume Labetalol 5mg/mL	Volume infusion fluid	Final volume 1mg/mL	50mL	200mL	250mL	60mL	240mL	300mL	100mL	400mL	500mL
	Volume Labetalol 5mg/mL	Volume infusion fluid	Final volume 1mg/mL											
50mL	200mL	250mL												
60mL	240mL	300mL												
100mL	400mL	500mL												
Infuse the prescribed dosage using a rate-controlled infusion pump. Refer to UpToDate for recommended dose based on indication.														
IV Infusion (Fluid restriction, unlicensed. Central line only)														
Draw up 300mg (60mL) of labetalol into a syringe neat to give a 5mg/mL infusion. Adjust rate according to response. Usual infusion rate of up to 2mg/min.														
Monitoring	Monitor blood pressure, heart rate, ECG, respiratory function.													
Extravasation	Extravasation may cause tissue damage. If a central venous access device is unavailable, administer via a large peripheral vein monitoring insertion site closely. Re-site cannula at first signs of inflammation.													
Additional Information	<div>For obstetric patients refer to CUMH guidelines or the Pharmacy Department</div>													
	Patient should avoid upright position during and for 3 hours after intravenous administration.													

Information provided relates to Trandate® (RPH Pharmaceuticals)

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications.
Further information is available from Pharmacy on 22146 or 22542*